Every year, Fierce Healthcare's editorial team sifts through hundreds of nominations to identify 15 companies that are truly making waves in the healthcare sector, striving to change the world by changing the industry. The 2024 class of Fierce 15 honorees is no exception, taking on some of the most pressing challenges in healthcare today. 

This episode features a conversation with Fierce Healthcare's Paige Minemyer, Dave Muoio and Noah Tong. They share insights into this year's Fierce 15, discussing the companies that made the cut and the significant issues they are addressing.  

To learn more about the topics in this episode: 
Fierce Healthcare's Fierce 15 of 2024

Every year, Fierce Healthcare's editorial team sifts through hundreds of nominations to identify 15 companies that are truly making waves in the healthcare sector, striving to change the world by changing the industry. The 2024 class of Fierce 15 honorees is no exception, taking on some of the most pressing challenges in healthcare today. 
This episode features a conversation with Fierce Healthcare's Paige Minemyer, Dave Muoio and Noah Tong. They share insights into this year's Fierce 15, discussing the companies that made the cut and the significant issues they are addressing.  
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercehealthcare.com/special-reports/fierce-healthcares-fierce-15-2024" data-cke-saved-href="https://www.fiercehealthcare.com/special-reports/fierce-healthcares-fierce-15-2024">Fierce Healthcare's Fierce 15 of 2024</a></li>
</ul>

Podnosis: the pulse of the healthcare industry. Every week, journalists from Fierce Healthcare dive into some of the industry’s biggest trends. We talk to the experts about what’s important now so you can prep for the future. Hear about all things healthcare, from physician practices to hospital chains and insurance giants—and those that mix all three—plus the tech they use, disruptors looking to compete and people moving the sector forward. Follow Podnosis on Apple Podcasts, Spotify, Amazon or wherever you get your podcasts.

Podnosis: the pulse of the healthcare industry. Every week, journalists from Fierce Healthcare dive into some of the industry’s biggest trends. We talk to the experts about what’s important now so you can prep for the future. Hear about all things healthcare, from physician practices to hospital chains and insurance giants—and those that mix all three—plus the tech they use, disruptors looking to compete and people moving the sector forward. Follow Podnosis on Apple Podcasts, Spotify, Amazon or wherever you get your podcasts.

Podnosis

Podnosis: the pulse of the healthcare industry. Every week, journalists from Fierce Healthcare dive into some of the industry’s biggest trends. We talk to the experts about what’s important now so you can prep for the future. Hear about all things healthcare, from physician practices to hospital chains and insurance giants—and those that mix all three—plus the tech they use, disruptors looking to compete and people moving the sector forward. Follow Podnosis on Apple Podcasts, Spotify, Amazon or wherever you get your podcasts.

The Fierce 15 of 2024

Fertility services—and conversations about them—are expanding across the U.S. But the sector remains underregulated, expensive and, in some cases, outdated.

These factors are reshaping how Americans seek care, sometimes in ways that may put quality and safety at risk. Where are the biggest gaps? And what would make the system safer?

Senior Writer Anastassia Gliadkovskaya breaks it down with Brian Levine, M.D., founding partner and practice director of CCRM Fertility of New York and founder of Nodal, a platform connecting surrogates and intended parents.

To learn more about the topics in this episode: 
Trump admin takes aim at the cost of IVF with new coverage guidance
Women's health sector could grow to $600B industry by 2030: PwC report
Emotional support crucial in addition to financial support for fertility journey, Maven finds

Fertility services&mdash;and conversations about them&mdash;are expanding across the U.S. But the sector remains underregulated, expensive and, in some cases, outdated.
These factors are reshaping how Americans seek care, sometimes in ways that may put quality and safety at risk. Where are the biggest gaps? And what would make the system safer?
Senior Writer Anastassia Gliadkovskaya breaks it down with Brian Levine, M.D., founding partner and practice director of CCRM Fertility of New York and founder of Nodal, a platform connecting surrogates and intended parents.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercehealthcare.com/regulatory/trump-admin-takes-aim-cost-ivf-new-coverage-guidance">Trump admin takes aim at the cost of IVF with new coverage guidance</a></li>
<li><a href="https://www.fiercehealthcare.com/providers/womens-health-sector-could-grow-600b-industry-2030-new-report-says">Women's health sector could grow to $600B industry by 2030: PwC report</a></li>
<li><a href="https://www.fiercehealthcare.com/providers/emotional-toll-fertility-journeys-maven-survey-finds">Emotional support crucial in addition to financial support for fertility journey, Maven finds</a></li>
</ul>

Inside the gaps in fertility and surrogacy systems

In this sponsored episode of Podnosis, experts examine how molecular residual disease testing is transforming how clinicians assess recurrence risk in triple-negative breast cancer. Drawing on new data from the NSABP B-59 substudy presented at SABCS and AACR, the discussion highlights how circulating tumor DNA is providing earlier and more precise insight into patient outcomes.

Dr. Priya Rastogi, chief medical officer of the NSABP Foundation, explains how MRD testing can detect residual disease that standard tools may miss, often months or years before clinical recurrence. The conversation explores key findings, including the strong correlation between post-surgical ctDNA positivity and recurrence risk, as well as the prognostic value of ctDNA status earlier in the treatment pathway.

In this sponsored episode of Podnosis, experts examine how molecular residual disease testing is transforming how clinicians assess recurrence risk in triple-negative breast cancer. Drawing on new data from the NSABP B-59 substudy presented at SABCS and AACR, the discussion highlights how circulating tumor DNA is providing earlier and more precise insight into patient outcomes. Dr. Priya Rastogi, chief medical officer of the NSABP Foundation, explains how MRD testing can detect residual disease that standard tools may miss, often months or years before clinical recurrence. The conversation explores key findings, including the strong correlation between post-surgical ctDNA positivity and recurrence risk, as well as the prognostic value of ctDNA status earlier in the treatment pathway.

How MRD Testing Is Reshaping Breast Cancer Risk Assessment (Sponsored)

Condoms can be purchased almost anywhere, from big retailers to small convenience stores. The same can’t be said for female birth control. One company is trying to change that.

Cadence OTC sells the morning-after pill, a cheaper alternative to Plan B. Recognizing that many communities in the U.S. are pharmacy deserts, the company is pursuing atypical distribution channels such as convenience stores and gas stations to get emergency contraceptives into the hands of more Americans. Cadence is also advocating for a daily birth control pill to be made available over the counter.

Senior Writer Anastassia Gliadkovskaya sits down with Cadence OTC co-founder and CEO Samantha Miller to discuss how this approach could reshape reproductive healthcare and what policy and awareness challenges remain.

To learn more about the topics in this episode: 
Insurers not covering 12-month contraception supply as required: study
The quiet collapse of America's reproductive health safety net
Perrigo's over-the-counter birth control launch takes flight in the US
Amid Trump victory, women's health providers see flood of orders for contraception, abortion pills

Condoms can be purchased almost anywhere, from big retailers to small convenience stores. The same can&rsquo;t be said for female birth control. One company is trying to change that.
Cadence OTC sells the morning-after pill, a cheaper alternative to Plan B. Recognizing that many communities in the U.S. are pharmacy deserts, the company is pursuing atypical distribution channels such as convenience stores and gas stations to get emergency contraceptives into the hands of more Americans. Cadence is also advocating for a daily birth control pill to be made available over the counter.
Senior Writer Anastassia Gliadkovskaya sits down with Cadence OTC co-founder and CEO Samantha Miller to discuss how this approach could reshape reproductive healthcare and what policy and awareness challenges remain.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercehealthcare.com/payers/insurers-not-covering-12-month-contraception-supply-required-study">Insurers not covering 12-month contraception supply as required: study</a></li>
<li><a href="https://www.fiercehealthcare.com/providers/quiet-collapse-americas-reproductive-health-safety-net">The quiet collapse of America's reproductive health safety net</a></li>
<li><a href="https://www.fiercepharma.com/pharma/perrigos-over-counter-birth-control-launch-takes-flight-us">Perrigo's over-the-counter birth control launch takes flight in the US</a></li>
<li><a href="https://www.fiercehealthcare.com/digital-health/amid-trump-victory-womens-health-providers-see-flood-orders-contraception-abortion">Amid Trump victory, women's health providers see flood of orders for contraception, abortion pills</a></li>
</ul>

The Fierce 15 of 2024

In 1 playlist(s)

Podnosis

Social links

Follow podcast

Recent clips